187 related articles for article (PubMed ID: 30787430)
1. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.
Follo MY; Pellagatti A; Armstrong RN; Ratti S; Mongiorgi S; De Fanti S; Bochicchio MT; Russo D; Gobbi M; Miglino M; Parisi S; Martinelli G; Cavo M; Luiselli D; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L
Leukemia; 2019 Sep; 33(9):2276-2290. PubMed ID: 30787430
[TBL] [Abstract][Full Text] [Related]
2. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Mongiorgi S; De Stefano A; Ratti S; Indio V; Astolfi A; Casalin I; Pellagatti A; Paolini S; Parisi S; Cavo M; Pession A; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L; Follo MY
Clin Epigenetics; 2023 Feb; 15(1):27. PubMed ID: 36803590
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Sekeres MA; Tiu RV; Komrokji R; Lancet J; Advani AS; Afable M; Englehaupt R; Juersivich J; Cuthbertson D; Paleveda J; Tabarroki A; Visconte V; Makishima H; Jerez A; Paquette R; List AF; Maciejewski JP
Blood; 2012 Dec; 120(25):4945-51. PubMed ID: 22915641
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
[TBL] [Abstract][Full Text] [Related]
8. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.
Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
Oncotarget; 2016 Apr; 7(16):22103-15. PubMed ID: 26959885
[TBL] [Abstract][Full Text] [Related]
9. [Current diagnosis and treatment for myelodysplastc syndromes].
Hata T
Rinsho Ketsueki; 2017; 58(4):373-380. PubMed ID: 28484169
[TBL] [Abstract][Full Text] [Related]
10. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
Kenealy M; Hertzberg M; Benson W; Taylor K; Cunningham I; Stevenson W; Hiwase D; Eek R; Zantomio D; Jong S; Wall M; Blombery P; Gerber T; Debrincat M; Zannino D; Seymour JF
Haematologica; 2019 Apr; 104(4):700-709. PubMed ID: 30545923
[TBL] [Abstract][Full Text] [Related]
13. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
15. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Medeiros BC; McCaul K; Kambhampati S; Pollyea DA; Kumar R; Silverman LR; Kew A; Saini L; Beach CL; Vij R; Wang X; Zhong J; Gale RP
Haematologica; 2018 Jan; 103(1):101-106. PubMed ID: 29097499
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with
Wang X; Xiao Z; Qin T; Xu Z; Jia Y; Qu S; Li B; Pan L; Gao Q; Jiao M; Gale RP
Hematology; 2024 Dec; 29(1):2338509. PubMed ID: 38597818
[TBL] [Abstract][Full Text] [Related]
19. Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes.
Wei AH; Seymour JF
Br J Haematol; 2022 Aug; 198(3):415-418. PubMed ID: 35544384
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Stahl M; Zeidan AM
Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]